Safety Shot Exposed: A Phony Alcohol Detox Drink Backed by a Fake Study and Peddled by Shady Cast of Characters Using Aggressive Stock Promotion

Safety Shot Inc.'s (NASDAQ: SHOT) alcohol detox drink that claims to reduce blood alcohol content by 50% in 30 minutes is exposed as scientifically impossible by Capybara Research, which predicts the stock could fall to zero amid revelations of management's troubling financial histories and aggressive stock promotion tactics.

Ticker: SHOT (NASDAQ)
Research Firm: Capybara Research
Report URL: https://capybararesearch.com/reports/safety-shot-exposed/Position Disclosure: Capybara Research holds a short position in Safety Shot (SHOT) and stands to profit if the company's share price declines. Readers should weigh this financial interest accordingly when evaluating the report's claims and conclusions.

Why It Matters

Safety Shot's core product claim—reducing blood alcohol content by 50% in 30 minutes—is physiologically impossible and contradicts established medical science
Management has extensive ties to Stratton Oakmont (the infamous firm from "Wolf of Wall Street") and troubling histories of bankruptcies, tax liens, and unpaid debts
The company falsely claims its product is backed by a decade of research and $1M investment, but GBB Drink Labs was only formed in June 2020
No verifiable patents exist despite company claims of a "patented formula"
Aggressive stock promotion tactics include paying up to $150,000 to third-party promoters with histories of pumping fraudulent stocks
Significant dilution risk exists through convertible notes, outstanding warrants, and a $95M shelf offering

What's Next

CEO Brian John has a history of federal tax liens, bankruptcy, and foreclosures; previously worked with notorious Stratton Oakmont
The drink's claim to "convert alcohol to sugar" fundamentally misunderstands human physiology—alcohol is metabolized in the liver and not converted to sugar
Safety Shot has pivoted from failed CBD ventures to unrelated businesses, including a bizarre acquisition of SRM Entertainment, a toy company
CFO Markita Russell faces multiple lawsuits for unpaid personal debts, raising questions about her financial management capabilities
The company's rapid stock price increase appears driven primarily by paid promotional campaigns rather than legitimate business developments
Safety Shot circumvents FDA regulations by marketing the drink as a "nutraceutical" despite making drug-like efficacy claims

FAQs

What scientific evidence contradicts Safety Shot's claims?

Medical consensus from institutions like Stanford University and the National Institute on Alcohol Abuse and Alcoholism confirms that nothing can rapidly decrease BAC except time. The liver metabolizes alcohol at a fixed rate of approximately one standard drink per hour, making Safety Shot's claims physiologically impossible.

Who is behind Safety Shot and what is their background?

Safety Shot's management team includes several individuals with troubling financial and professional histories. CEO Brian John has multiple federal tax liens, a Chapter 7 bankruptcy, and foreclosure proceedings. He and other executives have connections to Stratton Oakmont, the notorious brokerage firm known for securities fraud and pump-and-dump schemes.

How is Safety Shot promoting its stock?

The company has engaged in aggressive stock promotion through third-party services like Secret Alerts, Planet MicroCap, and websites such as Nasdaqpicks.com. These promoters have reportedly been paid up to $150,000 for campaigns and have histories of promoting other stocks that later collapsed.

What happened to Safety Shot's previous business ventures?

Before pivoting to the alcohol detox drink, Safety Shot (previously Jupiter Wellness) focused on CBD products. The company has made several abrupt strategic shifts, including acquiring SRM Entertainment, a toy and souvenir designer—moves that suggest opportunistic pivoting rather than coherent business strategy.

What risks do Safety Shot investors face?

Investors face significant dilution risk from over 9 million unexercised warrants, convertible notes, and a $95 million shelf offering. The company's market capitalization exceeds $180 million despite questionable product claims, management issues, and an erratic business strategy.

Has Safety Shot's product been approved by the FDA?

No. Safety Shot avoids FDA scrutiny by marketing its product as a "nutraceutical" rather than a drug, despite making claims about blood alcohol content reduction that would typically require rigorous clinical testing and FDA approval if marketed as a pharmaceutical.

Disclaimer: This summary is not primary research and does not constitute investment advice. It is a brief overview of a detailed equity research report authored by the firm, organization, or source referenced in this article or at https://capybararesearch.com/reports/safety-shot-exposed/, which contains extensive evidence, regulatory filings, and analysis; readers are encouraged to review the full report there for a comprehensive understanding. The content provided in this publication is not authored or originated by us — we act solely as a distributor and do not endorse, verify, or take responsibility for the accuracy, completeness, or reliability of the information presented. This publication is for informational purposes only and should not be construed as legal, business, investment, or tax advice. Always conduct independent due diligence and consult qualified professionals before making any decisions based on the information contained herein. We disclaim all liability for any loss or damage arising from reliance on third-party content, and the views expressed are solely those of the respective source and do not necessarily reflect our own.